Skip to content
Business Times – Lifestyle
Author:
TiumBio
TiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line R/M HNSCC at ASCO 2026
May 31, 2026